Tuberculosis Clinical Trial
Official title:
A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis
Verified date | August 2020 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This research is being done to determine if Nitazoxanide (NTZ) will cause a significant decrease in the number of M. tuberculosis bacteria in sputum after 14 days of treatment. The study is being conducted at the GHESKIO Centers in Port au Prince Haiti
Status | Completed |
Enrollment | 30 |
Est. completion date | April 11, 2018 |
Est. primary completion date | April 11, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men and women ages 18 - 65 - Diagnosed with pulmonary tuberculosis via: sputum-microscopy smear-positive (2+ or 3+) within 14 days plus Sputum GeneXpert positive within 14 days plus Chest radiograph consistent with M. tuberculosis within 14 days - TB treatment naïve at time of enrollment - Bodyweight > 40kg - Negative HIV test within 30 days - Able to complete activities of daily living (ADLs) - All participants must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) - All female participants must agree to use barrier methods such as condoms as well as hormonal contraception for dual prophylaxis. - Able to give informed consent and demonstrate understanding of this study and willingness to participate in this study - Willing to be hospitalized for 2 weeks Exclusion Criteria: - Pregnancy - Evidence of complications of M. tuberculosis such as hemoptysis or shortness of breath - Extrapulmonary manifestations of M. tuberculosis - History of prior active tuberculosis - Evidence of rifampin resistance via GeneXpert - Previous diagnosis of diabetes or suggestion of impaired glucose metabolism via random plasma glucose - Previous diagnosis of HIV by any rapid HIV test or by ELISA - Any of the following lab abnormalities: Creatinine > 1.5 times the ULN; Random glucose > 2 times the ULN; ALT, AST, or alkaline phosphatase > 2 times the ULN; Hemoglobin < 7.5 g/dL - Any participant currently taking antimycobacterial therapy or within the past 30 days - Any concomitant illness that could compromise patient safety in this trial such as renal failure, chronic liver disease or alcoholic dependency - Enrolled in another clinical trial |
Country | Name | City | State |
---|---|---|---|
Haiti | Les Centres GHESKIO | Port-au-Prince |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
Haiti,
de Carvalho LP, Lin G, Jiang X, Nathan C. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J Med Chem. 2009 Oct 8;52(19):5789-92. doi: 10.1021/jm9010719. — View Citation
Shigyo K, Ocheretina O, Merveille YM, Johnson WD, Pape JW, Nathan CF, Fitzgerald DW. Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013 Jun;57(6):2834-7. doi: 10.1128/AAC.02542-12. Epub 2013 Mar 18. — View Citation
Stockis A, De Bruyn S, Gengler C, Rosillon D. Nitazoxanide pharmacokinetics and tolerability in man during 7 days dosing with 0.5 g and 1 g b.i.d. Int J Clin Pharmacol Ther. 2002 May;40(5):221-7. — View Citation
Walsh KF, McAulay K, Lee MH, Vilbrun SC, Mathurin L, Jean Francois D, Zimmerman M, Kaya F, Zhang N, Saito K, Ocheretina O, Savic R, Dartois V, Johnson WD, Pape JW, Nathan C, Fitzgerald DW. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tu — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | time to positivity (TTP) | To assess the change in time in hours to positive (TTP) signal in an automated liquid media culture system (BACTEC MGIT 960, Becton Dickinson) in participants receiving NTZ over 14 days | first 14 days of anti-tuberculosis therapy | |
Secondary | Number of participants with treatment-related adverse events as determined by DAIDS toxicity tables | To assess the safety of 1000 mg twice daily dosing of NTZ in participants with drug-sensitive tuberculosis by grading each treatment-related adverse reaction according the DAIDS Toxicity tables (November 2014) | first 14 days of anti-tuberculosis therapy | |
Secondary | Maximum plasma concentration of NTZ | To assess the maximum plasma concentration of NTZ via collection of whole blood samples at hours 2, 4, 6 after ingestion of 1000 mg NTZ on day 5 and day 14 of the study | first 14 days of anti-tuberculosis therapy | |
Secondary | Most probable number of M tuberculosis in 1 ml of sputum | To quantify the number of M. tuberculosis (MTB) in sputum at baseline and at day 14 using most probable number (MPN) micro-plate assay with and without resuscitation factors added to media | first 14 days of anti-tuberculosis therapy | |
Secondary | First-line drug susceptibility (DST) of Mycobacterium tuberculosis via Mycobacterial Growth Indicator System (MGIT) | To test for first-line drug susceptibility (DST) of Mycobacterium tuberculosis to isoniazid, rifampin, pyrazinamide and ethambutol via MGIT | first 14 days of anti-tuberculosis therapy | |
Secondary | Quantification of change in urine metabolites and correlation with change in TTP | To quantify the change in urine metabolites by LC-MS technology and the correlation of this change with change in TTP. | first 14 days of anti-tuberculosis therapy | |
Secondary | Minimum plasma concentration of NTZ | To assess the minimum plasma concentration of NTZ via collection of whole blood samples at 30 minutes prior to ingestion of 1000 mg of NTZ on day 5 and day 14 of the study | first 14 days of anti-tuberculosis therapy | |
Secondary | Area under the curve of NTZ metabolites | To assess the area under the curve of NTZ metabolites (tizoxanide, tizoxanide glucuronide) via collection of whole blood samples at hour 2, 4, and 6 post-ingestion of 1000 mg of NTZ on day 5 and day 14 | first 14 days of anti-tuberculosis therapy | |
Secondary | Sputum concentration of NTZ | To assess the sputum concentration of NTZ via collection of spot sputum samples 4 hours post-ingestion of 1000 mg NTZ on day 5 and day 14 of study | first 14 days of anti-tuberculosis therapy | |
Secondary | Change in Minimum inhibitory concentration (MIC) of NTZ against Tuberculosis over 14 days | To assess the MIC of NTZ against tuberculosis using microplate assay at baseline and again at day 14 to determine any change in the MIC over the course of treatment | first 14 days of anti-tuberculosis therapy | |
Secondary | Change in phylogeny of bacteria determined by sequencing of amplified 16S ribosomal DNA and/or metagenomic sequencing of bacterial DNA | Change in phylogeny of bacteria determined by sequencing of amplified 16S ribosomal DNA and/or metagenomic sequencing of bacterial DNA over the course of 14 days and correlation of this change with change in TTP. | first 14 days of anti-tuberculosis therapy | |
Secondary | Transcriptional signature of treatment response using whole blood transcriptional profiles | Determine the transcriptional signature of treatment response using whole blood transcriptional profiles obtained at baseline and day 14 | first 14 days of anti-tuberculosis therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |